Feasibility assessment of measles and rubella eradication.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
16 06 2021
Historique:
received: 05 04 2021
accepted: 14 04 2021
pubmed: 29 5 2021
medline: 9 7 2021
entrez: 28 5 2021
Statut: ppublish

Résumé

This report addresses the epidemiological aspects and feasibility of measles and rubella eradication and the potential resource requirements in response to the request of the Director-General at the Seventieth World Health Assembly held on May 31, 2017. A guiding principle is that the path toward measles and rubella eradication should serve to strengthen primary health care, promote universal health coverage, and be a pathfinder for new vision and strategy for immunization over the next decade as laid out in the Immunization Agenda 2030. Specifically, this report: 1) highlights the importance of measles and rubella as global health priorities; 2) reviews the current global measles and rubella situation; 3) summarizes prior assessments of the feasibility of measles and rubella eradication; 4) assesses the progress and challenges in achieving regional measles and rubella elimination; 5) assesses additional considerations for measles and rubella eradication, including the results of modelling and economic analyses; 6) assesses the implications of establishing a measles and rubella eradication goal and the process for setting an eradication target date; 7) proposes a framework for determining preconditions for setting a target date for measles and rubella eradication and how these preconditions should be understood and used; and 8) concludes with recommendations endorsed by SAGE.

Identifiants

pubmed: 34045102
pii: S0264-410X(21)00474-6
doi: 10.1016/j.vaccine.2021.04.027
pii:
doi:

Substances chimiques

Measles Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3544-3559

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

William J Moss (WJ)

International Vaccine Access Center, Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: wmoss1@jhu.edu.

Stephanie Shendale (S)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Ann Lindstrand (A)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Katherine L O'Brien (KL)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Nikki Turner (N)

Division of General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand.

Tracey Goodman (T)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Katrina Kretsinger (K)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH